Clinical Trial Update: Cellular Immunotherapy in Recipients of HLA-matched, Living Donor Kidney Transplants [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating cellular immunotherapy in recipients of HLA-matched living-donor kidney transplants has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplant Rejection

Drugs mentioned

• Cellular immunotherapy for kidney transplant

Snippet

Sponsor: Medeor Therapeutics, Inc. | Conditions: Kidney Transplant Rejection | Phase 3 | Status: COMPLETED